Cue Biopharma vs Foghorn Therapeutics
CUE and FHTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CUE and FHTX compare
Foghorn Therapeutics is the larger company, worth 5.3 times as much as Cue Biopharma ($109M against $20.6M).
Cue Biopharma grew revenue faster over the last twelve months (354% versus 52.0% for Foghorn Therapeutics).
Foghorn Therapeutics keeps more of each dollar of sales as profit, with a net margin of −176% compared with −436% at Cue Biopharma.
Foghorn Therapeutics scores higher on the StockData Score (9 against 8 for Cue Biopharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CUE | FHTX |
|---|---|---|
| Size and price | ||
| Market cap | $20.6M | $109M |
| Share price | $2.83 | $1.83 |
| Change, 1 year | −85.0% | −61.0% |
| Change, 5 years | −99.3% | −86.6% |
| Beta (5Y) | – | 2.82 |
| Employees | 29 | 106 |
| StockData Score | ||
| Total score | 8 | 9 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 | 2 |
| Performance score | 1 | 1 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.5× (better) | 3.0× |
| P/B | 8.9× | – |
| FCF yield | −244% | −77.6% (better) |
| Growth | ||
| Revenue growth (TTM) | 354% (better) | 52.0% |
| Revenue growth, 5Y average | 54.2% | 135% (better) |
| Profitability | ||
| Operating margin | −262% | −198% (better) |
| Net margin | −436% | −176% (better) |
| FCF margin | −133% (better) | −229% |
| Return on equity | −1603% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 1.25 | 3.36 (better) |
| Altman Z-score | −32.75 | −4.61 (better) |
| Piotroski F-score | 5 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 22.6% | 75.6% |
| Held by insiders | 17.4% | 36.3% |
| Insider net buying, 12 months | −$2.3M | – |
| Short interest, % of float | 14.4% | 6.0% |
Go deeper
- CUE stock overview
- CUE income statement
- CUE valuation and score
- FHTX stock overview
- FHTX income statement
- FHTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.